NCT02442427 - "Palivizumab Therapy for RSV-bronchiolitis" | Biotech Hunter

Enrollment

420

Participants

Timeline

Start Date

September 30, 2014

Primary Completion Date

February 1, 2018

Study Completion Date

February 1, 2018

Conditions

Respiratory Syncytial Virus-bronchiolitis

Interventions

DRUG

Palivizumab

A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.

OTHER

Placebo

An equal volume of 0.9% normal saline

Trial Locations (1)

3050

Hamad Medical Corporation, Doha